Breaking News

Valanx Biotech Secures €3 million in Latest Round of Financing

Will advance the biotech company's lead antibody-drug conjugate (ADC) program.

Author Image

By: Charlie Sternberg

Associate Editor

Valanx Biotech, a biotech company developing a technology for site-selectable, site-specific protein conjugation, has secured €3 million to advance its lead antibody-drug conjugate (ADC) program. The round of financing includes Foundation Fournier-Majoie and FUJIFILM Corporation as new investors, joining existing VC investors xista science ventures, tecnet equity, SOSV and angel investors Urs Spitz and SkyGene. The financing will enable pre-clinical development of VLX-ADC-001, a LIV-1-targeti...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters